Idera Pharmaceuticals Announces Effectiveness of Reverse Split
June 29 2006 - 5:00PM
Business Wire
Idera Pharmaceuticals (AMEX: IDP) announced today that its
previously declared one-for-eight reverse stock split became
effective at the close of business today. Beginning tomorrow,
Idera's common shares will begin trading on a reverse
split-adjusted basis. The stock symbol (IDP) will remain unchanged.
The Company's common stock will also trade under a new CUSIP number
beginning tomorrow as a result of the reverse split. Stockholders
who have existing stock certificates will receive instructions from
the Company's transfer agent, Mellon Investor Services, LLC, on how
to exchange their stock certificates. About Idera Pharmaceuticals,
Inc. Idera Pharmaceuticals is a drug discovery and development
company with a pipeline of drug candidates to treat cancer,
infectious, respiratory, and autoimmune diseases. Idera's
proprietary drug candidates are designed to modulate Toll-like
Receptors (TLRs,) the body's first line of immune defense. Idera's
pioneering DNA chemistry expertise enables it to identify drug
candidates for internal development and creates opportunities to
develop multiple collaborative alliances. Idera's most advanced
clinical candidate, IMO-2055, is an agonist of TLR9 and is
currently in a Phase 2 trial in oncology, and in a Phase 1/2
chemotherapy combination trial in oncology. Idera has selected a
second TLR9 agonist, IMO-2125, as a lead candidate for treating
infectious diseases. Idera also is collaborating with Novartis for
the discovery, optimization, development, and commercialization of
additional TLR9 agonist candidates for asthma and allergy. For more
information, visit www.iderapharma.com. Forward Looking Statements
This press release contains forward-looking statements concerning
Idera Pharmaceuticals, Inc. that involve a number of risks and
uncertainties. For this purpose, any statements contained herein
that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the
words "believes," "anticipates," "plans," "expects," "estimates,"
"intends," "should," "could," "will," "may," and similar
expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause Idera's
actual results to differ materially from those indicated by such
forward-looking statements, including the potential impact of the
announced reverse stock split on our stock price and such other
important factors as are set forth under the caption "Risk Factors"
in Idera's Quarterly Report on Form 10-Q filed on May 12, 2006,
which important factors are incorporated herein by reference. Idera
disclaims any intention or obligation to update any forward-looking
statements.
Idera Pharmaceutical (AMEX:IDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Idera Pharmaceutical (AMEX:IDP)
Historical Stock Chart
From Jul 2023 to Jul 2024